Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Alzheimer's disease drug research most recently characterized by setbacks, not breakthroughs, the field is shifting toward a biomarker-based approach that will allow for the treatment of patients earlier in the course of the disease – before they show symptoms.
You may also be interested in...
Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials
FDA says consistent training program needed for market implementation of amyloid diagnostic. Lilly says issues will be resolved promptly.
Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent
Bristol's Early Alzheimer's Research Takes A Different Tack
Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop